var data={"title":"Tromethamine (THAM) (United States: Not available): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tromethamine (THAM) (United States: Not available): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7120?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tromethamine-tham-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Tromethamine (THAM) (United States: Not available): Drug information&quot;</a> and <a href=\"topic.htm?path=tromethamine-tham-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tromethamine (THAM) (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232038\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tham [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062803\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Alkalinizing Agent, Parenteral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445210\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Tham solution is no longer available in the US. <b>Note:</b> Dose dependent upon severity and progression of acidosis; doses should be administered slowly to prevent overtreatment. Tromethamine is available as a 0.3 M solution (THAM); doses are based on this concentration and expressed as volumes (mL/kg).  Each mL of THAM = 0.3 mmol = 36 mg = 0.3 mEq</p>\n    <p style=\"text-indent:0em;margin-right:2em;\">\n      <b>Metabolic acidosis with respiratory distress syndrome (RDS):</b> IV:</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-right:2em;\">Manufacturer's labeling: 1 mL/kg for each pH unit below 7.4; additional doses to be determined by changes in PaO<sub>2</sub>, pH, and pCO<sub>2</sub></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing (Nahas1998): Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dose (mL) of THAM = body weight (kg) &times; base deficit (mEq/L)</p>\n    <p style=\"text-indent:0em;margin-left:4em;margin-right:2em;\">\n      <b>Note:</b> The maximum dose recommended for neonates with normal renal function is 5 to 7 mmol/kg/day; lower doses may be needed in patients with renal dysfunction. In general, dose should be delivered slowly, over 1 hour in premature neonates. Use of a small loading dose  (25% of the calculated dose) over 5 to 10 minutes through an umbilical or peripheral vein followed by remainder of the dose over 1 hour has been reported (Gupta 1967; Nahas 1998; Strauss 1968).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062799\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tromethamine-tham-united-states-not-available-drug-information\" class=\"drug drug_general\">see &quot;Tromethamine (THAM) (United States: Not available): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Tham solution is no longer available in the US. <b>Note:</b> Dose dependent upon severity and progression of acidosis; doses should be administered slowly to prevent overtreatment. Tromethamine is available as a 0.3 M solution (THAM); doses are based on this concentration and expressed as volumes (mL/kg).  Each mL of THAM = 0.3 mmol = 36 mg = 0.3 mEq </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Metabolic acidosis:</b> Infants, Children, and Adolescents: IV: Empiric dosage based upon base deficit: Dose (mL) of THAM = body weight (kg) x base deficit (mEq/L) x 1.1*</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual range: 1 to 2 mEq/kg/dose; maximum dose in 24 hours: 15 mEq/kg/24 hours (15 mmol/kg/24 hours) (Kliegman 2007; Nahas 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">*Factor of 1.1 accounts for an approximate reduction of 10% in buffering capacity due to the presence of sufficient acetic acid to lower the pH of the 0.3 M solution to approximately 8.6  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Metabolic acidosis with cardiac arrest:</b> Limited data available: <b>Note:</b> Routine use of buffering agents during cardiac arrest not recommended (AHA [Klienman 2010]): Infants, Children, and Adolescents: THAM: IV: 1 mL/kg should raise bicarbonate concentration by 1 mEq/L (Fuhrman 2011)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Metabolic acidosis with cardiac arrest:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 3.6 to 10.8 g (111 to 333 mL); additional amounts may be required to control acidosis after arrest reversed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Open chest: Intraventricular: 2 to 6 g (62 to 185 mL). <b>Note:</b> Do not inject into cardiac muscle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acidosis associated with cardiac bypass surgery:</b> IV: Average dose: 9 mL/kg (2.7 mEq/kg); 500 mL is adequate for most adults; maximum dose: 500 mg/kg over at least 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Excess acidity of acid citrate dextrose (ACD) blood in cardiac bypass surgery:</b> 15 to 77 mL of 0.3 molar solution added to each 500 mL of ACD blood </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232027\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tham: 30 mEq/100 mL (500 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232014\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46720770\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Tham solution is no longer available in the US.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062806\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV infusion: Infuse undiluted solution (0.3 M) slowly </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: Metabolic acidosis: Administer over at least 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Correction of metabolic acidosis in cardiac bypass surgery: Administer by slow IV infusion over at least 1 hour (maximum rate: 500 mg/kg over at least 1 hour); rapid administration may result in prolonged hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Correction of metabolic acidosis in cardiac arrest:  If chest is not open, inject into a large peripheral vein.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant (with IV administration); ensure proper needle or catheter placement prior to and during administration; avoid extravasation. If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3341466\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from freezing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062805\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Correction of severe metabolic acidosis in patients in whom sodium or carbon dioxide elimination is restricted (eg, infants needing alkalinization after receiving maximum sodium bicarbonate [8 to 10 mEq/kg/24 hours]) (FDA approved in pediatric patients [age not specified] and adults); correction of metabolic acidosis associated with cardiac bypass surgery or cardiac arrest (FDA approved in adults); to correct excess acidity of stored blood that is preserved with acid citrate dextrose (ACD) (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3123324\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tromethamine may be confused with TrophAmine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232055\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Localized phlebitis, venospasm</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperkalemia, hypervolemia, hypoglycemia (usually doses &gt;500 mg/kg administered over &lt;1 hour)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic necrosis (resulted during delivery via umbilical venous catheter)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, pulmonary edema, respiratory depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232033\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to tromethamine or any component of the formulation; uremia or anuria; chronic respiratory acidosis (neonates); salicylate intoxication (neonates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232018\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation. May cause tissue inflammation and necrosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypoglycemia: May cause hypoglycemia with extremely large doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory depression: May cause respiratory depression; monitor closely especially if patient not intubated. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; reduce dose and monitor pH carefully.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Duration of therapy: Drug should not be given for a period of longer than 24 hours unless for a life-threatening situation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25955959\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid infusion via low-lying umbilical venous catheters (particularly with concentrations &ge;1.2 M) due to associated risk of hepatocellular necrosis; severe local tissue necrosis and sloughing may occur if solution extravasates; administer via central line or large vein slowly. Due to the greater osmotic effects of tromethamine, use of sodium bicarbonate for the treatment of acidotic neonates and infants with RDS may be preferred; may cause prolonged hypoglycemia in neonates or with rapid IV infusion and overdosage. Monitor pH carefully as large doses may increase blood pH greater than normal which may result in depressed respiration. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300183\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223545\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12868&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Tromethamine may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232023\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3341462\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit outweighs possible risk to the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062802\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, arterial blood gases, serum pH, blood sugar, ECG monitoring, renal function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232017\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\"> Acts as a proton acceptor, which combines with hydrogen ions, liberating  bicarbonate buffer, to correct acidosis. It buffers both metabolic and respiratory acids, limiting carbon dioxide generation. Also an osmotic diuretic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232032\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes quickly into extracellular space; at steady state distributes into a volume slightly greater than total body water; penetrates slowly intracellularly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 5.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&gt;75%) within 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324044\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tham Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mEq/100 mL (500 mL): $291.06</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992801\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Addex-Tham (SE);</li>\n      <li>Tham (DE, GR);</li>\n      <li>Thamesol (IT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta JM, Dahlenburg GW, Davis JA. Changes in blood gas tensions following administration of amine buffer THAM to infants with respiratory distress syndrome. <i>Arch Dis Child</i>. 1967;42(224):416-427.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tromethamine-tham-united-states-not-available-pediatric-drug-information/abstract-text/4951641 /pubmed\" target=\"_blank\" id=\"4951641 \">4951641 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tromethamine-tham-united-states-not-available-pediatric-drug-information/abstract-text/20956230 /pubmed\" target=\"_blank\" id=\"20956230 \">20956230 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahas GG, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. <i>Drugs</i>. 1998;55(2):191-224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tromethamine-tham-united-states-not-available-pediatric-drug-information/abstract-text/9506241 /pubmed\" target=\"_blank\" id=\"9506241 \">9506241 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strauss J. Tris (hydroxymethyl) amino-methane (Tham): a pediatric evaluation.<i> Pediatrics</i>. 1968;41(3):667-689.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tromethamine-tham-united-states-not-available-pediatric-drug-information/abstract-text/4868611 /pubmed\" target=\"_blank\" id=\"4868611 \">4868611 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tham solution for injection (tromethamine) [prescribing information]. Lake Forest, IL: Hospira, Inc; October 2005.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12868 Version 67.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F232038\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062803\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445210\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062799\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232027\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F232014\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46720770\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062806\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3341466\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062805\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3123324\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F232055\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232033\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232018\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25955959\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300183\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223545\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F232023\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3341462\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062802\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232017\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F232032\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324044\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992801\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12868|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tromethamine-tham-united-states-not-available-drug-information\" class=\"drug drug_general\">Tromethamine (THAM) (United States: Not available): Drug information</a></li><li><a href=\"topic.htm?path=tromethamine-tham-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Tromethamine (THAM) (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}